Who founded Trio Pharmaceuticals?

Trio Pharmaceuticals was founded by H. Kim Lyerly in 2018.

Who are Trio Pharmaceuticals's investors?

Trio Pharmaceuticals's investors include NuFund Venture Group.

How much funding has Trio Pharmaceuticals raised?

Trio Pharmaceuticals has disclosed $1.9M raised across 1 round.

Where is Trio Pharmaceuticals headquartered?

Trio Pharmaceuticals is headquartered in San Diego, US.

Trio Pharmaceuticals

San Diego, US · Founded 2018 · Delaware corporation · 3 known investors

Trio Pharmaceuticals develops dual-targeting antibody drugs to treat cancer, using its TIE-ADC and TRAILBody platforms to kill cancer cells and overcome tumor immunosuppression while reducing treatment-related toxicity. Its pipeline targets blood cancers (AML/MDS), ovarian and endometrial cancers, and triple-negative breast and non-small cell lung cancers.

Biotech Healthtech

Founders & leadership

Trio Pharmaceuticals was founded in 2018 by H. Kim Lyerly.

H. Kim LyerlyinCMO & Founder

Reiner LausNamed on SEC filing

Shivarupam BhowmikNamed on SEC filing

Jeffrey FriedmanNamed on SEC filing

Investors · 3

NuFund Venture Groupreported · 2 sourcesSan Diego · $1M

Also in the syndicate · 2

Friedman BioVenturesleadNewsight Tech Angels Inc.

Reported raises · per SEC filings

Form D private placements

$1.9M disclosed across 1 round · 2022

▶$1.9MraisedDec 2022 · 9 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Reiner LausExecutive Officer, Director
Shivarupam BhowmikExecutive Officer, Director
Jeffrey FriedmanDirector

Offering amount: $2.4M
Amount sold: $1.9M
First sale: Nov 2022
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Solu18 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Bioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Trio Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Trio Pharmaceuticals Raises $2.2 Million Seed - San Diego Business Journalsdbj.com · Apr 2023

Frequently asked questions

What does Trio Pharmaceuticals do?: Trio Pharmaceuticals develops dual-targeting antibody drugs to treat cancer, using its TIE-ADC and TRAILBody platforms to kill cancer cells and overcome tumor immunosuppression while reducing treatment-related toxicity. Its pipeline targets blood cancers (AML/MDS), ovarian and endometrial cancers, and triple-negative breast and non-small cell lung cancers.
Who founded Trio Pharmaceuticals?: Trio Pharmaceuticals was founded by H. Kim Lyerly in 2018.
Who are Trio Pharmaceuticals's investors?: Trio Pharmaceuticals's investors include NuFund Venture Group.
How much funding has Trio Pharmaceuticals raised?: Trio Pharmaceuticals has disclosed $1.9M raised across 1 round.
Where is Trio Pharmaceuticals headquartered?: Trio Pharmaceuticals is headquartered in San Diego, US.